Press coverage about ANI Pharmaceuticals (NASDAQ:ANIP) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. ANI Pharmaceuticals earned a news impact score of 0.04 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 45.7377485233384 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

ANIP has been the topic of a number of recent analyst reports. TheStreet upgraded ANI Pharmaceuticals from a “c+” rating to a “b” rating in a report on Thursday, November 16th. Zacks Investment Research upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a report on Tuesday, November 7th. ValuEngine raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 4th. Canaccord Genuity reissued a “buy” rating on shares of ANI Pharmaceuticals in a research report on Thursday, November 2nd. Finally, BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, January 5th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $71.00.

Shares of ANI Pharmaceuticals (NASDAQ ANIP) opened at $70.32 on Wednesday. ANI Pharmaceuticals has a 1 year low of $42.23 and a 1 year high of $74.70. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 3.45. The firm has a market capitalization of $842.51, a P/E ratio of 109.88 and a beta of 2.90.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The company had revenue of $48.16 million during the quarter, compared to analysts’ expectations of $48.12 million. During the same period last year, the firm earned $1.09 EPS. The firm’s revenue for the quarter was up 25.0% on a year-over-year basis. equities analysts predict that ANI Pharmaceuticals will post 3.59 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Stock Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related stocks with our FREE daily email newsletter.